

CAREFUSION Corp  
Form 425  
October 06, 2014

FILED BY BECTON, DICKINSON AND COMPANY

PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933 AND

DEEMED FILED PURSUANT TO RULE 14A-12 OF THE SECURITIES EXCHANGE ACT OF 1934

SUBJECT COMPANY: CAREFUSION CORP

COMMISSION FILE NO. 001-34273

The following is a transcript of a video made available on the website that is being maintained at [www.bdcarefusion.transactionannouncement.com](http://www.bdcarefusion.transactionannouncement.com).

### **VIDEO TRANSCRIPT**

**Vincent A. Forlenza:** BD is doing this transaction to bring together two great companies to improve a very important process in the hospital that's medication management. It's an area of big concern for hospitals. Both companies have complementary products that can be brought together to simplify this process and improve it. This is a perfect fit. It's a perfect fit for BD, it's a perfect fit for our customers.

The second reason is these companies are a perfect fit from a geographical standpoint. BD has invested in a global infrastructure, CareFusion has been very U.S. focused and trying to build out that infrastructure, but this accelerates that strategy for both of the companies. So all of these elements together are very exciting.

**Kieran T. Gallahue:** It's a great example of taking two very aligned organizations from a cultural perspective, but that have complementary strengths. Whether it's a geographic perspective or whether it's from a product perspective and we fit together like really truly wonderful pieces of a puzzle.

You know our, at CareFusion our focus has been on lowering the cost of care while improving patient safety, and doing so in a way to try to touch patients around the globe. This helps accelerate that vision.

**VF:** Together, we can improve healthcare both in medication management and in procedural solutions. Both of those opportunities are exciting for BD and CareFusion and within the global context.

Both companies have tremendous clinical knowledge, and we can bring that knowledge to bear around the globe whether it's in China or Brazil, in Europe or in the US, and when you bring that knowledge together we're going to improve healthcare. We believe we can do that together and we can do it better together.

**KG:** You know, hospitals around the globe, healthcare systems around the globe, are struggling with the reality that they need to do more with less. They need to be able to manage a demographic which suggests aging populations, more on developing economies, be able to reach more patients that, to date, have not been able to have access to quality care.

**VF:** BD is a stronger company today, with more opportunity for people across the entire company. We remain focused and committed to our businesses on the diagnostic and bioscience side of the business. We have major R&D programs that will continue to move ahead. We see great opportunity within those businesses to grow and we are going to drive those strategies.

So my vision for BD is a more innovative, more global, more impactful company, and today we get up and we have more capability to fulfill that vision than we had yesterday in fact, tremendously more capability. So as I look to the future, I see a company that has the ability to impact problems in healthcare around the globe with a scale that we did not have before to help all people live healthy lives and do it faster and more impactful.

\* \* \*

### **Forward-Looking Statements**

*This communication contains certain estimates and other forward-looking statements (as defined under Federal securities laws). Forward looking statements generally are accompanied by words such as will, expect, outlook or other similar words, phrases or expressions. These forward-looking statements include statements regarding the estimated or anticipated future results of BD, and of the combined company following BD's proposed acquisition of CareFusion, the anticipated benefits of the proposed combination, including estimated synergies, the expected timing of completion of the transaction and other statements that are not historical facts. These statements are based on the current expectations of BD and CareFusion management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding BD and CareFusion's respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the ability of the parties to successfully close the proposed acquisition, including the risk that the required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transaction; risks relating to the integration of CareFusion's operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; the outcome of any legal proceedings related to the proposed merger; access to available financing for the refinancing of BD's or CareFusion's debt on a timely basis and reasonable terms; the ability to market and sell CareFusion's products in new markets, including the ability to obtain necessary regulatory product registrations and clearances; the loss of key senior management or other associates; the anticipated demand for BD's and CareFusion's products, including the risk of future reductions in government healthcare funding, changes in reimbursement rates or changes in healthcare practices that could result in lower utilization rates or pricing pressures; the impact of competition in the medical device industry; the risks of fluctuations in interest or foreign currency exchange rates; product liability claims; difficulties inherent in product development, including the timing or outcome of product development efforts, the ability to obtain regulatory approvals and clearances and the timing and market success of product launches; risks relating to fluctuations in the cost and availability of raw materials and other sourced products and the ability to maintain favorable supplier arrangements and relationships; successful compliance with governmental regulations applicable to BD, CareFusion and the combined company; changes in regional, national or foreign economic conditions; uncertainties of litigation, as well*

as other factors discussed in BD's and CareFusion's respective filings with the Securities Exchange Commission. BD and CareFusion do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.

### **IMPORTANT INFORMATION FOR INVESTORS**

In connection with the proposed transaction, BD will file with the SEC a registration statement on Form S-4 that will constitute a prospectus of BD and include a proxy statement of CareFusion. BD and CareFusion also plan to file other relevant documents with the SEC regarding the proposed transaction. **INVESTORS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.** You may obtain a free copy of the proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by BD and CareFusion with the SEC at the SEC's website at [www.sec.gov](http://www.sec.gov). In addition, you will be able to obtain free copies of these documents by phone, e-mail or written request by contacting the investor relations department of BD or CareFusion at the following: Monique N. Dolecki, Investor Relations 201-847-5378 [Monique\\_Dolecki@bd.com](mailto:Monique_Dolecki@bd.com) or Jim Mazzola, Investor Relations 858-617-1203 [Jim.Mazzola@CareFusion.com](mailto:Jim.Mazzola@CareFusion.com)

### **PARTICIPANTS IN THE SOLICITATION**

BD and CareFusion and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about BD's directors and executive officers is available in BD's proxy statement dated December 19, 2013, for its 2014 Annual Meeting of Shareholders and subsequent SEC filings. Information about CareFusion's directors and executive officers is available in CareFusion's proxy statement dated September 25, 2014, for its 2014 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from BD or CareFusion as indicated above. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.